Alexander KM Leung - In vivo Anti-tumour Activity of Corilagin of Hep3B Hepatocellular Carinoma

Document created by Alexander KM Leung on Aug 22, 2014
Version 1Show Document
  • View in full screen mode

  Publication Details (including relevant citation   information):

  Phytomedicine,  Vol.   18(1), 11-15 (2010)


  We have investigated the potential in vivo anti-tumour   activity of corilagin using the Hep3B hepatocellular carcinoma   cell line and an athymic nude mice xenograft model. The purity of   corilagin was confirmed by high performance liquid   chromatographic analysis. Corilagin was administrated   intraperitoneally for a continuous period of 7 days at a   concentration of 15 mg/kg of body weight per day. A significant   inhibition of tumour growth was observed when treated mice are   compared with control groups. Furthermore, analysis of enzymes   markers of liver function, including alanine aminotransferase and   asparate aminotransferase, suggested that current therapeutic   dosage of corilagin did not exert adverse effect on liver. Our   observations support the view that corilagin is considerably   effective to retard the in vivo growth of xenografted   Hep3B hepatocellular carcinoma.

  Address (URL):